AUUM is dedicated to developing and manufacturing superior nutritional products to support the health of all.
Our mission: Through constant research, development and observation AUUM will bring the very best omega-3 products to the world in order to improve the health of everyone including our children, the future generation.
Our vision: To build a dynamic company that is a leader in the development of scientifically based nutrition supplements that can support health and provide targeted nutrition therapy for individuals or their pets diagnosed with chronic diseases.
2003 - AUUM Inc. was a manufacturer of hemp based Omega-3 skin care products and began R&D with with seal oil to add long-chain anti-inflammatory Omega-3s into products.
2006 - Internal and external research revealed that seal oil omega-3s were a superior source of omega-3s because of their unique structure and higher digestibility compared to fish oil. AUUM started to produce and market mammalian Omega-3 capsules.
2007 - Continued R&D by AUUM enabled the development of Sublingual-D, the first omega-3 product designed for sublingually delivery of omega-3s.
2008/2010 - Building on the success of AUUM Sublingual-D, AUUM D3A was developed to allow for sublingual delivery of vitamin A, D and omega-3s. Both products were used to support the work of the Balanced Heart Mission and its’ studies with Autistic Children. The overwhelming feedback from this work was that supplementation with AUUM Sublingual-D or D3A improved speech and behaviour.
2012 - Researchers at the University of Toronto, Department of Nutritional Science used AUUM Sublingual-D in a clinical trial investigating the effect of omega-3 supplementation on nerve function and exercise performance. Findings showed 21-days of AUUM Sublingual-D increased muscle activation 9% and reduced sprint cycling fatigue 5% compared to placebo.
2013 - AUUM was the product sponsored of the first clinical trial to investigate the therapeutic use of omega-3s to stop the progression of nerve damage in Diabetic Neuropathy. The trial, funded by the Canadian Diabetes Association is being conducted by researchers at the University of Toronto - Department of Nutritional Sciences, Toronto General Hospital - Division of Neurology and the Mt. Sinai Hospital - Leadership Centre for Diabetes. Study findings will report on the effect of AUUM omega-3s on changes in nerve structure and nerve function. The results will be presented at 14th International Congress on Neuromuscular Disease, July 2016 in Toronto, Canada.
2014 - AUUM was the product sponsored for a Canadian Cancer Society funded double-blind clinical trial in chemotherapy induced peripheral neuropathy. This trial is being conducted by researchers at the McGill University Health Centre - Segal Cancer Centre. The study is ongoing, and results will be available in 2017.
2016 - Stay tuned for the results of the Diabetic Neuropathy trial and the introduction of the AUUM Professional Product Line.